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Study objectives: To estimate annual incidence of community acquired pneumonia
(CAP) in an Italian general population sample.
Design and participants: Two hundred and eighty-seven family practitioners (64.6%
of those selected) recorded suspected or ascertained CAP cases for 1 year.
Information on smoking habit, respiratory symptoms and signs, co-morbidity,
antibiotic and corticosteroid therapy, hospitalization, mortality and recovery were
obtained.
Results: Six hundred and ninety-nine case forms were collected (53.1% females,
mean age 59.6719.5, 20.6% smokers). CAP incidence rates per 1000 population
were: 1.69 in men vs. 1.71 in women; 2.33 in the North vs. 1.29 in the Centre-South
of Italy; between 0.73 in 14-, and 3.34 in 64+year-old subjects. Main symptoms and
signs were cough (73.3%), crackles (72.8%), dullness (57.3%), asthenia (53.4%). 59.5%
of subjects had concurrent diseases, mostly cardiac and respiratory. 77.2% of casesElsevier Ltd. All rights reserved.
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Epidemiological survey and treatment 47had chest X-ray (with parenchymal density in 90.6%). Phlegm microbiological
examination was performed in 12.8% of cases. First choice antibiotics were
cephalosporins (45.8%), macrolides (20.2%), other b-lactams (18.6%), and fluoroqui-
nolones (12.2%). Rates of hospitalization and of mortality were 31.8% and 6.0%,
respectively.
Conclusion: This study confirmed that the annual CAP incidence rate in the general
population of South Europe is about 2 per 1000 population and showed a wide choice
of antibiotic treatment.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Lower respiratory tract infections (LRTIs), including
pneumonia, account for elevated morbidity and
mortality rates worldwide. In UK, respiratory
infections are the most frequent cause of family
practitioner (FP) consultation, accounting for about
6% of visits,1 whereas hospital admissions for lung
infections account for 4.4% of the total.2
In Italy, data collected by the Ministry of Health3
throughout the Diagnosis Related Groups system
indicate that in 1998 there were 113,766 hospital
admissions for ‘‘simple pneumonia and pleurisy’’,
corresponding to 1.16% of total hospital admissions.
A more detailed analysis carried out in the Latium
Region on data spanning from 1997 to 19994 reports
an annual incidence of 158 hospital admissions per
100,000 population, with case fatality rates of 9.4%
and 29.3% for community acquired pneumonia
(CAP) and nosocomial pneumonia, respectively. In
any case, wide variations in mortality have been
found even in countries of similar social and health
conditions such as Italy, UK and the USA, with rates
ranging from 5 to 100 cases per year per 100,000
population.5,6
Unfortunately, CAP is not subject to mandatory
notification; therefore incidence rates cannot be
deducted from the routinely collected
statistics. Few cohort studies have been so far
carried out in North-Europe and UK, and they
have obtained figures ranging between 4.7
and 11.6 cases per year per 1000 population.7–9
Recently, incidence rates less than 2% in an
area of Barcelona, Spain, and in two US
cohort studies (Health Professionals Follow-up
Study and Nurses’ Health Study) have been re-
ported.10,11 Comparable data, although expressed
in a different way and on a limited sample size, had
been observed in France12: 1.72 CAP cases per FP
per year. Further, among the few European coun-
tries for which incidence rates of pneumonia have
been mapped in the 2003 European Respiratory
Society (ERS) White Book on Respiratory Diseases,13
Italy was not included due to lack of published
reports.Therefore, the aim of this paper is to describe
the findings of a study designed to estimate the
incidence rate of CAP and its treatment in Italy as
reported by FPs during an observational period of 1
year.Materials and methods
The epidemiological survey on the incidence of CAP
in Italy (EPI-CAP 1999–2000 study) was planned by
the Working Groups ‘‘Epidemiology’’ and ‘‘Respira-
tory Pathophysiology’’ of the Italian Association of
Hospital Pneumologists (AIPO), by the Working
Group ‘‘Epidemiology’’ of the Italian Society of
Respiratory Medicine (SIMeR) and by the Italian
Society of General Practitioners (SIMG), with the
collaboration of the Pulmonary Environmental
Epidemiology Unit of the CNR Institute of Clinical
Physiology, Pisa.
A random sample of FPs living in 40 Italian
provinces was selected. The provinces were chosen
according to their closeness to the microbiological
laboratories participating in a project of Epidemio-
logical Monitoring of microorganisms causing re-
spiratory infections, sponsored by SmithKline
Beecham Italy. Whenever possible, FPs were se-
lected among those affiliated to SIMG, which kindly
provided us the list of its affiliates. In those areas
where there were too few SIMG members, physi-
cians were randomly selected from the province
telephone directory.
The calculation of the population sample size
was performed on the basis of an expected CAP
incidence of 5 cases per year per 1000 population
and by hypothesising a difference of 1% between
the incidence in Northern Italy and the incidence in
Central-Southern Italy, with a power of 90%. In
order to obtain the expected number of physicians
to be involved, the population sample size was
divided by the average number of registered
citizens for each physician. Thus, considering a
conservative estimate of 1000 citizens per each
physician, the expected number of FPs resulted
ARTICLE IN PRESS
G. Viegi et al.48234. However, to accommodate for a possible large
rate of dropout, such number was increased by
92%. Thus, 449 FPs were randomly selected.
Each selected FP was sent by courier mail the
investigation tools and a letter explaining aim and
methods of the study, along with the invitation to
collect new cases of suspected CAP in the period
February 15, 1999–February 14, 2000. At intervals,
telephone calls to keep the physicians motivated
were made during the study period.
There were two forms to collect data: the ‘‘white
form’’, for each suspected CAP directly formulated by
the FP, regardless of chest X-ray or laboratory
confirmation; the ‘‘blue form’’, for each CAP diag-
nosed at the hospital where the patient had gone
directly or had been sent by another physician on
night-times or on week-ends, of whom the FP knew
the conditions at the discharge from the hospital.
The ‘‘white form’’ was used to collect informa-
tion on: subject’s initials, anthropometric data,
smoking habit, respiratory and systemic symptoms/
diseases, corticosteroids and/or antibiotics taken
in the last 30 days, diagnostic procedure (blood
tests, serology, microbiology, chest X-ray), 1st and
2nd choice antibiotic treatment, hospitalization,
and final outcome.
The ‘‘blue form’’ was used to collect information
on: subject’s initials, anthropometric data, respira-
tory and systemic diseases, conditions at hospital
discharge, length of hospital stay, and antibiotic
treatment at discharge.
Each FP was requested to follow his/her usual
management and care procedures, with the excep-
tion of the invitation to ask the patient to collect a
phlegm specimen to be analysed at the closest
microbiological laboratory participating in the
project. For this purpose, each FP received 10
containers for phlegm specimens to deliver to
patients when needed.
Quarterly the forms were sent to the Pisa
coordinating centre and fed into the computer.
Statistical analyses were performed with the
Statistical Package for the Social Sciences (SPSS)
version 10.0 for Windows. Frequency distribution,
w2, analyses of variance were used to describe
categorical and continuous variables, as well as
multiple logistic regression models to identify risk
factors for CAP incidence. A P-value of 0.05 was
considered statistically significant.Results
The overall participation rate of FPs in the study
was 64% (287 out of the 449 invited FP; 81.1%affiliated to SIMG). These participants sent 699
data forms to the coordinating centre. There were
548 (78.4%) ‘‘white forms’’ reporting information
on diagnostic suspicion formulated directly by FP
(COM) and 151 (21.6%) ‘‘blue forms’’ reporting
information on diagnosis made within the hospital
(HOS).
Anthropometric characteristics, residence and
smoking habits are reported in Table 1. Numbers
vary in the categories due to different missing
values. There were slightly more women (53.1%)
than men (46.9%). HOS subjects were older than
COM subjects of about 9.1 years. A total of 94.4%
lived at home and 5.6% in a nursing home. There
were 20.6% smokers, 26.7% ex smokers and 52.7%
non-smokers. COM subjects showed a lower propor-
tion of ex smokers, whilst HOS subjects had lower
frequencies of smokers and non-smokers. When we
assessed possible differences between SIMG and
no-SIMG FP, we found that the former reported data
on slightly older patients (60.0719.1 vs. 58.47
18.7 years, Po0:05) who lived less frequently in
nursing homes (3.7% vs. 10.4%).
Annual CAP incidence per 1000 population was
calculated on the basis of the average number of
citizens enrolled in FP lists (Table 2). CAP incidence
was slightly higher in women (1.713%) than in men
(1.692%). There was a geographical gradient
according to the inverse of latitude (North:
2.332% vs. Centre-South 1.288%). The rate in-
creased with ageing ranging from 0.734% in
children less than 14 years up to 3.338% in the
elderly (64+year). There was no difference be-
tween SIMG and no-SIMG FP.
The following analyses refer to the 548 COM
subjects. Most frequently reported symptoms were
those of new onset (Table 3): cough (73.3%),
asthenia (53.4%), dyspnea (43.3%), phlegm (43.1%)
(mucous-purulent in 44.3% of cases), chest pain
(50.0%). Almost 89.1% of subjects had fever, and
59.5% exhibited one or more concurrent diseases,
mainly hypertension (33.0%), chronic bronchitis
(22.3%), emphysema (18.9%), heart diseases
(23.3%). When compared to no-SIMG FP ones, SIMG
FP’s patients had slightly increased frequencies of
dullness (60.1 vs. 50.3%, Po0:05), dyspnea (new
onset: 47.2 vs. 33.6%, worsened 13.7% vs. 5.4%,
Po0:05), tachypnea (41.8 vs. 26.8%, Po0:05) and a
slightly lower frequency of phlegm (new onset:
37.8 vs. 56.7, worsened 19.2 vs. 12.0%, Po0:05).
With regard to chest physical examination, new
onset of crackles (72.8%) and dullness (57.3%)
showed the highest prevalence rates (Table 4).
413 subjects (77.2%) performed chest X-ray. Rea-
sons of not performance were logistical difficulties
(50.8%), patient’s refusal (8.2%), deemed as not
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Table 1 Subjects’ characteristics: gender, anthropometric measures, habitual residence, smoking habit,
comorbidity.
Community Hospital
Sex (n ¼ 699)
Males (n ¼ 328) 256 (46.7%) 72 (47.7%)
Females (n ¼ 371) 292 (53.3%) 79 (52.3%)
Anthropometric measuresy
Age (n ¼ 699), yr 57.6 (719.2) 66.7 (718.7)
Height (n ¼ 677), cm 167.8 (78.5) 165.3 (78.1)
Weight (n ¼ 679), kg 68.7 (714.7) 65.3 (713.0)
Usual residencey
House (n ¼ 642) 509 (95.3%) 133 (91.1%)
Resting home (n ¼ 38) 25 (4.7%) 13 (8.9%)
Smoking habitz
Smokers (n ¼ 141) 116 (21.7%) 25 (16.7%)
Ex smokers (n ¼ 183) 133 (24.9%) 50 (33.3%)
Non-smokers (n ¼ 361) 286 (53.5%) 75 (50.0%)
Comorbidity
Heart diseases (n ¼ 695)y 94 (17.3%) 68 (45.0%)
Neurological diseases (n ¼ 682)y 37 (6.9%) 25 (16.9%)
Diabetes (n ¼ 692) 57 (10.5%) 18 (12.2%)
Hypertension (n ¼ 694)z 164 (30.2%) 65 (43.0%)
Neoplasms (n ¼ 692) 49 (9.1%) 12 (7.9%)
Chronic bronchitis (n ¼ 676)z 118 (22.3%) 60 (40.8%)
Asthma (n ¼ 667)z 46 (8.7%) 23 (16.4%)
Emphysema (n ¼ 661)y 98 (18.9%) 49 (34.5%)
yPo0:05.
z0:054Po0:1.
yPo0:001:
zPo0:01.
Table 2 Incidence of pneumonia in EPI-CAP survey.
No. of CAP Mean of subjects registered per FP Total registered subjects Incidence (%)
Total 699 1430.082 410433.51 1.703
Males 328 675.526 193875.87 1.692
Females 371 754.556 216557.64 1.713
p14 years 10 47.353 13590.23 0.734
15–44 years 158 601.364 172591.60 0.915
45–64 years 207 443.193 127196.43 1.627
464 years 324 338.172 97055.25 3.338
North 380 1262.690 162887.01 2.332
Centre-South 319 1566.750 247546.50 1.288
Number of family practitioners: Total 287, North 129, Centre-South 158.
Epidemiological survey and treatment 49necessary by FP (41.0%). In almost all radiographs
there was one or more parenchymal densities.
Pleural effusion was reported in 45 subjects
(10.9%), almost always associated to parenchymal
density. Other unspecified broncho-pulmonary im-pairment was reported in 54 subjects (13.1%).
There was no difference between SIMG and no-
SIMG FP.
Very few subjects (12.8%) performed a micro-
biological phlegm examination. Reasons of not
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Table 3 Prevalence rates (%) of symptoms and
diseases in subjects with suspicion of CAP.
Symptoms
Cough (n ¼ 546)
New onset 73.3
Exacerbation 23.8
Phlegm* (n ¼ 536)
New onset 43.1
Exacerbation 17.2
Dyspnea (n ¼ 540)
New onset 43.3
Exacerbation 11.3
Dehydration (n ¼ 527)
New onset 8.3
Exacerbation 3.2
Asthenia (n ¼ 541)
New onset 53.4
Exacerbation 18.5
Confusion (n ¼ 532)
New onset 6.0
Exacerbation 5.5
Fever (n ¼ 542) 89.1
Chest pain (n ¼ 532) 50.0
Tachypnea (n ¼ 541) 37.5
Diseases
Heart diseases (n ¼ 695) 23.3
Neurological disease (n ¼ 681) 9.1
Diabetes (n ¼ 694) 10.8
Hypertension (n ¼ 694) 33.0
Neoplasms (n ¼ 693) 8.8
Chronic bronchitis (n ¼ 529) 22.3
Asthma (n ¼ 527) 8.7
Emphysema (n ¼ 519) 18.9
*Phlegm aspect (n ¼ 318): mucous 55.7%; mucous-puru-
lent 44.3%.
Table 4 Prevalence rates (%) of lung sounds and
chest X-ray findings in subjects with suspicion of
CAP.
Dullness (n ¼ 525) 57.3
Ronchi/wheezes (n ¼ 508) 50.6
Coarse crackles (n ¼ 537)
New onset 72.8
Worsening 11.9
Chest X-ray* carried out (n ¼ 535) 77.2
Chest X-ray carried out (n ¼ 413),
more answers
Increased parenchymal density 90.6
Pleural effusion 10.9
Other pulmonary signs 13.1
*Chest X-ray not performed n ¼ 122 (22.8%): 50.8% for
logistical reasons; 8.2% for patient’s refusal; 41.0%
deemed as not necessary by FP.
G. Viegi et al.50performance were lack of phlegm (27.2%), logis-
tical difficulties (48.5%), patient’s refusal (11.5%).
Antibiotics were prescribed as follows: cephalos-
porins (45.8%), macrolides (20.2%), other b-lactams
(18.6%), and fluoroquinolones (12.2%). In Table 5,
first choice antibiotics, singly or in combination,
are reported (mutually exclusive groups). Those
prescribed in more than 10% of cases were
cephalosporins (27.1%), macrolides (18.0%), other
b-lactams (13.0%), fluoroquinolones (12.0%), and
the combination cephalosporins plus macrolides
(11.7%).
Rates of hospitalization and of mortality on the
whole CAP population were 31.8% (11.5% for COM
subjects) and 6.0% (4.4% for COM subjects, 10.7%
for HOS subjects), respectively. There was no
difference between SIMG and no-SIMG FP in the
CAP management or outcome.
In Fig. 1, significant and borderline odds ratios to
have increased parenchymal density at chest X-ray
(derived from logistic regression model, accounting
for age, gender, residence, geographical area) are
reported for COM subjects. Cough, dyspnea, and
chest pain were the symptoms associated with the
health outcome. The risk was significantly in-
creased by the condition of being ever smoker,
whilst it was decreased by having neurological
disorders or asthma.
Heart diseases, neurological diseases, neo-
plasms, bronchial asthma, living in the Northern
geographical area and previous corticosteroid
therapy were significant risk factors for the
hospitalization (derived from logistic regression
model, accounting for age, gender, residence,
smoking habit) on the whole sample (COM and
HOS subjects) (Fig. 2).Discussion
The EPI-CAP 1999–2000 study has provided to our
knowledge the first estimates of CAP incidence in
Italy on the basis of a virtual sample of about
410,000 Italian citizens registered in the lists of 287
FPs.
The internal validity of the studied cases is shown
by the differences in some characteristics among
COM and HOS patients: the latter were older,
resided more frequently in nursing homes, were
less frequently current smokers and more fre-
quently ex smokers, reported more frequently co-
morbidities. Further, although there were few
differences of no clinical importance in anthropo-
metric characteristics, in symptoms and physical
examination among the patients followed by SIMG
ARTICLE IN PRESS
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Figure 1 Odds ratios (OR) and 95% confidence intervals
(95% CI) to have increased parenchymal density at chest
X-ray (derived from logistic regression model, accounting
for age, gender, residence, geographical area) among
COM subjects.
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Figure 2 Odds ratios (OR) and 95% confidence intervals
(95% CI) for the hospitalization (derived from logistic
regression model, accounting for age, gender, residence,
smoking habit) in the whole sample (COM and HOS
subjects).
Table 5 Frequency of antibiotics use in subjects with CAP suspicion, singly and in combination (mutually
exclusive group).
No. of cases % of use
Cephalosporins 144 27.1
Macrolides 96 18.0
b-Lactams 69 13.0
Fluoroquinolones 64 12.0
Cephalosporins+macrolides 62 11.7
Others 18 3.4
Cephalosporins+others 18 3.4
Cephalosporins+fluoroquinolones 17 3.2
b-Lactams+others 12 2.3
b-Lactams+macrolides 11 2.1
Macrolides+others 7 1.3
Macrolides+fluoroquinolones 5 0.9
b-Lactams+cephalosporins 2 0.4
b-Lactams+fluoroquinolones 2 0.4
Cephalosporins+fluoroquinolones+others 2 0.4
Fluoroquinolones+others 1 0.2
b-Lactams+macrolides+fluoroquinolones 1 0.2
b-Lactams+cephalosporins+macrolides 1 0.2
Epidemiological survey and treatment 51and no-SIMG FP, there was no difference between
SIMG and no-SIMG FP in the CAP management or
outcome.
The incidence rate of 1.703% is low with respect
to the expected CAP incidence of 5 cases per year
per 1000 population, as hypothesised prior to the
survey. This might be explained by a unidirectional
‘‘report bias’’,14 due to a tendency to report only
the most severe suspected cases of CAP with the
consequence of yielding conservative estimates.
Another possibility would be the missing of somecases directly hospitalized who might have omitted
to report the disease to their FP after the
discharge. Unfortunately, the coordinating centre
had no possibility to independently check the
completeness of the data forms provided by
physicians living in 40 Italian provinces. It is also
to point out that in Italy, children are quite
commonly referred directly to a paediatrician and
the incidence of CAP might be underestimated
using FPs as the sampling frame for subjects
younger than 15 years (n ¼ 10). However, we did
not find an incidence of CAP in the 15–44 years
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age-class. This result does not support the hypothesis
of a relevant referral bias for children in this study.
Conversely, the lack of radiological confirmation
in about one-fifth of cases let us hypothesise the
presence of a unidirectional ‘‘information bias’’ 14
determining an overestimate of CAP cases by
possible inclusion of people with acute exacerba-
tions of chronic bronchitis. However, among those
with chest X-ray, 97% were reported to have
parenchymal densities: it argues against a relevant
‘‘information bias’’.
Further, the age unbalance of our sample,
besides reflecting the ageing of the Italian popula-
tion (415% is now over 65 years), also corresponds
to the fact that the elderly have more often access
to primary care because they have more often co-
morbidity. Moreover, they also have increased risk
to get infectious diseases like pneumonia. Also such
an unbalance might cause a unidirectional bias
towards a possible overestimation of CAP incidence
rates due to the inclusion of subjects, which might
not have such disease.
In any case, the net result of these potential
opposite biases had likely a very minor effect on
the reliability of our estimates in so far as the
annual incidence rates of CAP found in the present
study are very close to the value of 1.62 per 1000
population found in Barcelona10 and to the value of
1.72 cases per FP found in France,12 and they are
lower than those reported in Northern-Europe and
UK.8–10 It should be noticed that, out of 13
European countries for which incidence rates of
pneumonia have been reported in the European
Respiratory Society White Book on Respiratory
Diseases,13 only Spain, France and the Czech
Republic have shown figures lower than 3% and
that Lithuania and Estonia have rates between 10%
and 14%, whilst Germany has an incidence rate of
16.87%. One could argue that some inaccuracies in
the estimates of CAP incidence rates might be
originated by the use of a virtual population in our
study. However, it would not be feasible to organize
a study in which all the about 410,000 registered
subjects had to be actively contacted by the FP for
1 year. Due to the inherent severity of CAP, it is
reasonable to assume that almost all cases have
approached their own physician, even if previously
managed by another professional or structure of
the National Health Service. Indeed, the consis-
tency of results in Italy and in other countries
strongly supports the validity of our approach.
In addition, the difference in the incidence rates
of North and Centre-South of Italy was 1.044%, i.e.
almost identical to the 1% estimate made prior to
the study. It is known that also pneumonia mortalityis lower in the South than in the North of Italy,15
although socio-economic conditions are on average
less wealthy in the former area. This may be a clue
of the beneficial effect of mild Mediterranean
climate on respiratory infections. Such a statement
is supported by recent evidences in the USA16
linking mortality to extreme temperatures and
showing beneficial effects of living in areas at mild
temperate climate.
The new onsets of fever, cough, asthenia, along
with crackles and dullness at chest physical
examination were the most important symptoms
and signs by which FPs were induced to formulate
the CAP diagnosis, confirming other reports in the
literature.17 However, it is well known that there is
a large inter-observer variation in recognising
certain findings18 and there are no individual
clinical findings, or combination of findings that
can rule in the diagnosis of pneumonia for a patient
suspected of having this illness.19 In any case,
although most patients with CAP can be managed
successfully in the community by their FP without
investigations, distinguishing CAP from other
causes of respiratory symptoms and signs in the
absence of further investigations can be difficult,
particularly when the presence of comorbidity,
such as left ventricular failure, chronic lung
disease, or COPD, contributes to increase the
complexity of clinical picture.20 Moreover, the
elderly frequently represent a particularly difficult
diagnostic challenge because of presence of non-
specific symptoms and signs.
Chronic bronchitis and emphysema, by showing
higher prevalence rates than in the general
population,21 confirm to be important risk factors
for CAP, along with hypertension and cardiovascular
disease.22 This evidence may be of pivotal impor-
tance when considering the opportunity of having a
more proactive behaviour towards preventive
measures in the primary care of these patients.
Almost 80% of subjects performed chest X-ray
and 11.6% did not due to reported logistic
difficulties. These figures can be considered an
acceptable CAP management in general practice.
Indeed, the guidelines of the Canadian Infectious
Disease Society and of the Canadian Thoracic
Society consider acceptable the empirical treat-
ment of CAP without radiological confirmation,
when it is difficult to go to the radiological clinic.23
However, 9.1% of subjects did not perform chest X-
ray since it was deemed as not necessary by FP. This
decision indicates an insufficient application of
international guidelines on diagnosis and manage-
ment of CAP, such as those of the Infectious Disease
Society of America (IDSA),24 American Thoracic
Society (ATS),25 and British Thoracic Society
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ray in the usual diagnostic procedures of suspected
CAP. Furthermore, as suggested by Lieberman et
al.,17 the ability of physicians to negate X-ray
confirmed pneumonia by clinical assessment in
febrile adult LRTI patients is good, but the ability
to successfully predict this condition is poor.
Phlegm was reported by 60.3% of patients, but
microbiological sputum examination was per-
formed in only 12.8%, mainly because of logistical
difficulties (48.4%), although each FP had been
provided of containers for phlegm collection and
the Microbiological Laboratories were not far from
the residential zones. It is to point out that the US
Pneumonia Patient Outcomes Research Team
(PORT) Cohort Study26 found that only 29.7% of
944 ambulatory CAP patients had undergone micro-
biological examinations and in only 5.7% was
possible to detect a specific cause of CAP. In any
case, the role of routine microbial investigation of
patients with pneumonia in the community27 and
even all adults admitted to hospital with CAP28
remains unclear. Thus, sputum collection has not
been recommended as part of a management
algorithm when a patient with CAP is treated in a
primary-care hospital that does not have on-site
microbiology facilities.29
The lack of information on pathogen microorgan-
ism makes it more difficult to comment the results
on antibiotic prescriptions by FPs. Indeed, mono-
therapy was chosen in 70.1%. Since 88.5% of these
patients were followed at home and were likely
affected by less severe forms of disease than those
requiring hospitalization, such management beha-
viour fits with the suggestions of main guidelines on
CAP treatment.20,23,25
Conversely, the empirical choice of the type of
antibiotic seems more questionable because it
generally diverged from recommendations of the
most important CAP treatment guidelines.20,23–25
However, diversities in local health systems,
sources of information at the clinician’s disposal30
and, more important, local therapeutic traditions,
and marketing factors can justify the observed
differences.31
Cephalosporins (45.8%) were prescribed in more
than a quarter (27.1%) singly and in about one fifth
(18.7%) in combination with other antibiotics. This
finding is in accordance with the previous docu-
mentation that third-generation cephalosporins are
the most frequent prescriptions in initial antibiotic
therapy for community LRTIs in Italy.32
The use of macrolides (18.0% singly, 20.2% in
combination) is more adherent to all practice
guidelines, although there are contraindications in
using such antibiotics as monotherapy because ofthe risk of Streptococcus pneumoniae strains
resistant to macrolide and azalide agents, despite
their excellent activity against most other patho-
gens.33,34
Fluoroquinolones were used in 12.0% singly and in
12.2% in combination. We must stress that, when
the survey was performed, only the 1998 IDSA
guidelines suggested the use of such antibiotics.35
Conversely, the infrequent use of other b-lactams
(13.0% singly, 18.6% in combination) seems to be in
contrast with the guidelines. Such limitation might
have been caused by the fear of the possibility that
penicillin-resistant microorganisms were the cause
of CAP.36,37 Indeed, the 1999 results of the Italian
Epidemiological Observatory showed that penicillin
resistance in S. pneumoniae was 10.2% with high
level resistance accounting for 4.1%. Amoxicillin,
co-amoxiclav and injectable third generation ce-
phalosporins were the only drugs capable of over-
coming intermediate resistance to penicillin in
most S. pneumoniae isolates.38
Although mortality rates were quite similar (6.0%
in Italy, 5% in Spain), hospitalization rate (31.8%)
was lower than in the Spanish study (61.4%)10
indicating possible differences in the severity of the
diseases and in the usual management of CAP by FP.
In Italy, heart diseases, neurological diseases,
neoplasm, asthma, living in the Northern geogra-
phical area and previous corticosteroid therapy
pneumonia were significant risk factors for the
hospitalisation, seeming to indicate an appropriate
management.
Overall, CAP continues to be an important socio-
economic burden in the year 2000, indicating the
need to implement preventative strategies through
the increase of the proportion of subjects vacci-
nated against influenza virus and against pneumo-
cocci. Recent data foster a wider use of
pneumococcal vaccine, especially in children and
in the elderly.39–40
In conclusion, this collaborative study of FP and
pulmonologists has confirmed that the annual CAP
incidence rate in the general population of South
Europe is slightly less than 2 per 1000 population
and has shown a wide choice of antibiotic treat-
ment.Acknowledgments
The authors thank all the FPs who collected the
data on their patients; Drs. G. Bettoncelli, L.
Milani, E. Turbil (SIMG) and Prof. V. Bellia (Uni-
versity of Palermo) for their advice in study design
and interpretation; Dr. M. Pedreschi, Mr. F. Di Pede,
ARTICLE IN PRESS
G. Viegi et al.54Mrs. A. Angino, G. Lazzeri, B. Piegaia, F. Martini,
Mr. M. Borbotti and Mrs. P. Silvi (EPAP Unit, IFC-
CNR, Pisa) for the organisation, the contacts with
FPs, the data feeding on PC, the statistical
analyses; Dr. B. de Bernardi and Mrs. M. Brescianelli
(at the time working with Smithkline Beecham,
Milan) for the general support.References
1. OPCS. Morbidity statistics from general practice. Fourth
National Study 1991–1992. London: HMO; 1995.
2. Anderson H, Esmail A, Hollowel J, et al. Epidemiologically
based needs assessment. Report 16. Lower Respiratory
Disease. NHS Management Executive, 1993.
3. Dati del Ministero della Salute. Ricoveri Ospedalieri anno
1998. Web site: www.ministerosalute.it
4. Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of
hospitalised pneumonia in Lazio, Italy, 1997–1999. Int
J Tuberc Lung Dis 2004;8:528–36.
5. Ward DJ, Ayres JG. Pneumonia and acute bronchitis. In:
Annesi-Maesano I, Gulsvik A, Viegi G, editors, Respiratory
epidemiology in Europe. Eur Respir 2000; 5(Mon 15): 105–27.
6. Viegi G, Carrozzi L, Desideri M, Boccuzzo G. Le malattie
dell’apparato respiratorio. La mortalita` in Italia nel periodo
1970–1992: evoluzione e geografia. Roma: ISTAT; 1999.
p. 213–37.
7. Macfarlane JT, Colville A, Guion A, et al. Prospective study
of aetiology and outcome of adult lower-respiratory-tract
infections in the community. Lancet 1993;341:511–4.
8. Woodhead MA, Macfarlane JT, McCracken JS, et al.
Prospective study of the aetiology and outcome of pneumo-
nia in the community. Lancet 1987;1:671–4.
9. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of
community-acquired pneumonia in the population of four
municipalities in eastern Finland. Am J Epidemiol 1993;
137:977–88.
10. Almirall J, Bolibar I, Vidal J, et al. Epidemiology of
community-acquired pneumonia in adults: a population-
based study. Eur Respir J 2000;15:757–63.
11. Baik I, Curhan GC, Rimm EB, et al. A prospective study of
age and lifestyle factors in relation to community-acquired
pneumonia in US men and women. Arch Intern Med 2000;
160:3082–8.
12. Laurichesse H, Robin F, Gerbaud L, et al. Empirical therapy
for non-hospitalized patients with community-acquired
pneumonia. Study Group of General Practitioners. Eur Respir
J 1998;11:73–8.
13. ERS/ELF. Pneumonia. In: Loddenkemper R, Gibson GJ, Sibille
Y, editors, European lung white book. ERS/ELF, 2003.
p. 55–65.
14. Last JM. A dictionary of epidemiology. New York: Oxford
University Press; 1998.
15. Viegi G, Carrozzi L, Desideri M, Boccuzzo G. Le malattie
dell’apparato respiratorio. In: La mortalita` in Italia nel
periodo 1970–1992: evoluzione e geografia. Roma: ISTAT;
1999. p. 213–37.
16. O’Neill MS, Zanobetti A, Schwartz J. Modifiers of the
temperature and mortality association in seven US cities.
Am J Epidemiol 2003;157:1074–82.
17. Lieberman D, Shvartzman P, Korsonsky I, Lieberman D.
Diagnosis of ambulatory community-acquired pneumonia.Comparison of clinical assessment versus chest X-ray. Scand
J Prim Health Care 2003;21:57–60.
18. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting
physical signs in examination of the chest. Lancet 1988;1:
873–5.
19. Metlay JP, Kapoor WN, Fine MJ. Does this patient have
community-acquired pneumonia? Diagnosing pneumonia by
history and physical examination. J Am Med Assoc 1997;278:
1440–5.
20. British Thoracic Society Standards of Care Committee. BTS
guidelines for the management of community acquired
pneumonia in adults. Thorax 2001;56(Suppl. IV):1–64.
21. Viegi G, Pedreschi M, Baldacci S, et al. Prevalence rates of
respiratory symptoms and diseases in general population
samples of North and Central Italy. Int J Tuberc Lung Dis
1999;3:1034–42.
22. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes
of patients with community-acquired pneumonia. A meta-
analysis. J Am Med Assoc 1996;275:134–41.
23. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian
guidelines for the initial management of community-
acquired pneumonia: an evidence-based update by the
Canadian Infectious Diseases Society and the
Canadian Thoracic Society. The Canadian Community-
Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:
383–421.
24. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines
for the management of community-acquired pneumonia in
adults. Infectious Diseases Society of America. Clin Infect
Dis 2000;31:347–82.
25. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for
the management of adults with community-acquired pneu-
monia. Diagnosis, assessment of severity, antimicrobial
therapy, and prevention. Am J Respir Crit Care Med 2001;
163:1730–54.
26. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes
of care for patients with community-acquired pneumonia:
results from the Pneumonia Patient Outcomes Research
Team (PORT) cohort study. Arch Intern Med 1999;159:
970–80.
27. Theerthakarai R, El-Halees W, Ismail M, et al. Nonvalue of
the initial microbiological studies in the management of
nonsevere community-acquired pneumonia. Chest
2001;119:181–4.
28. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, et al.
The value of routine microbial investigation in community-
acquired pneumonia. Respir Med 1991;85:313–7.
29. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying
sputum as a diagnostic tool in pneumonia: limited yield,
minimal impact on treatment decisions. Chest 2002;121:
1486–92.
30. Cazzola M, Centanni S, Blasi F. Have guidelines for the
management of community-acquired pneumonia influenced
outcomes? Respir Med 2003;97:205–11.
31. Cazzola M, Blasi F, Allegra L. Critical evaluation of guidelines
for the treatment of lower respiratory tract bacterial
infections. Respir Med 2001;95:95–108.
32. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial
antibiotic therapy for lower respiratory tract infection in the
community: a European survey. Eur Respir J 1996;9:1590–5.
33. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough
pneumococcal bacteremia in patients being treated with
azithromycin and clarithromycin. Clin Infect Dis 2000;31:
1008–11.
34. Gay K, Baughman W, Miller Y, Jackson D, et al. The emerg-
ence of Streptococcus pneumoniae resistant to macrolide
ARTICLE IN PRESS
Epidemiological survey and treatment 55antimicrobial agents: a 6-year population-based assessment.
J Infect Dis 2000;182:1417–24.
35. Bartlett JG, Breiman RF, Mandell LA, File Jr TM. Community-
acquired pneumonia in adults: guidelines for management.
The Infectious Diseases Society of America. Clin Infect Dis
1998;26:811–38.
36. Felmingham D, Washington J. Trends in the antimicrobial
susceptibility of bacterial respiratory tract pathogens—find-
ings of the Alexander Project 1992–1996. J Chemother
1999;11(Suppl. 1):5–21.
37. Craig WA. Introduction. Respir Med 2001;95(Suppl. A):
S2–4.38. Schito GC, Mannelli S, Marchese A, et al. Osservatorio
Epidemiologico Italiano: resistenza ai farmaci antimicrobici
in Streptococcus pneumoniae circolanti nel 1999 in Italia.
GIMMOC 2002;4:13–30.
39. Whitney CG, Farley MM, Hadler J, et al. Active Bacterial
Core Surveillance of the Emerging Infections Program
Network. Decline in invasive pneumococcal disease after
the introduction of protein-polysaccharide conjugate vac-
cine. N Engl J Med 2003;348:1737–46.
40. Jackson LA, Neuzil KM, Yu O, et al. Vaccine Safety Datalink.
Effectiveness of pneumococcal polysaccharide vaccine in
older adults. N Engl J Med 2003;348:1747–55.
